Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT02453919
Recruiting Observational

Register of Cardiovascular Complications Among People Living With HIV

NCT02453919 · tracked via the Priya Life Science France tracker
Sponsor
Saint Antoine University Hospital
Phase
Observational
Started
2010-02
Last updated
2024-01-30

Condition(s) studied

HIVCardiovascular Diseases

Study summary

The REgister of cardiovascular COmplications among people living with HIV (RECOVIH) is a single hospital registry of adults living with HIV, with one or more other cardiovascular risk factor, who undergo cardiac examination at the Cardiac Center of the Saint Antoine Hospital.

RECOVIH is an observational and prospective, monocentric (institutional) registry, with anonymized cardiac, biochemical and associated data collection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18 years of age or older * Known HIV-1 seropositivity for minimum of six months (confirmed by Elisa and Western Blot) * Underwent complete cardiac examination (echocardiography, ischemia test, ambulatory blood pressure monitoring) between 2005 and 2010 at the Cardiac Center in the Saint Antoine University Hospital in Paris, France * Presenting a minimum of two cardiovascular risk factors (HIV and a minimum of one other) according to the AFFSSAPS 2005 and Morlat Report 2013. * Willing and able to give informed consent to participate in the study Exclusion Criteria : * Refusal to give or sign informed consent * Not associated with a social security regime (no health insurance)

Primary outcome measure(s)

  • Cardiovascular mortality — 20 years
    Cardiovascular mortality as classified using the 10th revision of the International Classification of Diseases (cardiovascular diagnosis codes I 00-I 99).

Trial sites (1)

FacilityCityRegionStatus
Division of Cardiology, Saint Antoine University Hospital Paris France Recruiting

More Saint Antoine University Hospital trials in France

Thromboembolic and Bleeding Risk Stratification in Patients With Non-valvular Atrial Fibrillation Recruiting

Other trials for the same condition

Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study) Recruiting
Identification of New Biomarkers for the Prediction of Cardiovascular Events Recruiting
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) Active, not recruiting
Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States Recruiting
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02453919 on ClinicalTrials.gov ↗ ← All trials in France